Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Dec;18(1):21.
doi: 10.1186/s10194-017-0733-2. Epub 2017 Feb 13.

Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study

Claudine Angela Blum  1   2 , Bettina Winzeler  3 , Nicole Nigro  3 , Philipp Schuetz  4 , Silke Biethahn  5 , Timo Kahles  5 , Cornelia Mueller  3 , Katharina Timper  3   6 , Katharina Haaf  5 , Janina Tepperberg  5 , Margareth Amort  7 , Andreas Huber  8 , Roland Bingisser  9 , Peter Stephan Sándor  10 , Krassen Nedeltchev  5 , Beat Müller  4 , Mira Katan  11 , Mirjam Christ-Crain  3
Affiliations
Observational Study

Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study

Claudine Angela Blum et al. J Headache Pain. 2017 Dec.

Abstract

Background: In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious secondary headache and benign headache forms in the emergency setting.

Methods: Patients presenting with acute non-traumatic headache were prospectively enrolled into an observational cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease. Secondary endpoint was the combination of mortality and hospitalization within 3 months. Two board-certified neurologist blinded to copeptin levels verified the endpoints after a structured 3-month-telephone interview.

Results: Of the 391 patients included, 75 (19%) had a serious secondary headache. Copeptin was associated with serious secondary headache (OR 2.03, 95%CI 1.52-2.70, p < 0.0001). Area under the curve (AUC) for copeptin to identify the primary endpoint was 0.70 (0.63-0.76). After adjusting for age > 50, focal-neurological abnormalities, and thunderclap onset of symptoms, copeptin remained an independent predictive factor for serious secondary headache (OR 1.74, 95%CI 1.26-2.39, p = 0.001). Moreover, copeptin improved the AUC of the multivariate logistic clinical model (p-LR-test < 0.001). Even though copeptin values were higher in patients reaching the secondary endpoint, this association was not significant in multivariate logistic regression.

Conclusions: Copeptin was independently associated with serious secondary headache as compared to benign headaches forms. Copeptin may be a promising novel blood biomarker that should be further validated to rule out serious secondary headache in the emergency department.

Trial registration: Study Registration on 08/02/2010 as NCT01174901 at clinicaltrials.gov.

Keywords: Biomarker; Copeptin; Emergency; Head pain; Headache; Vasopressin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
STROBE study flow diagram
Fig. 2
Fig. 2
Boxplot of copeptin values
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schonenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Muller B, Pro Hsg Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007;7:102. doi: 10.1186/1472-6963-7-102. - DOI - PMC - PubMed
    1. Locker T, Mason S, Rigby A. Headache management--are we doing enough? An observational study of patients presenting with headache to the emergency department. Emerg Med J. 2004;21:327–332. doi: 10.1136/emj.2003.012351. - DOI - PMC - PubMed
    1. Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin KR, Grotta JC, Shaw SG, Knudson L, Frankowski RF. Headache in the emergency department. Headache. 2001;41:537–541. doi: 10.1046/j.1526-4610.2001.041006537.x. - DOI - PubMed
    1. Stevenson RJ, Dutta D, MacWalter RS. The management of acute headache in adults in an acute admissions unit. Scott Med J. 1998;43:173–176. doi: 10.1177/003693309804300605. - DOI - PubMed
    1. Ang SH, Chan YC, Mahadevan M. Emergency department headache admissions in an acute care hospital:why do they occur and what can we do about it? Ann Acad Med Singapore. 2009;38:1007–1010. - PubMed

Publication types

Associated data